Published in J Virol on April 01, 1970
Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus. J Virol (1987) 1.72
Immunological and biophysical separation of dengue-2 antigens. J Virol (1971) 1.66
Structural and nonstructural proteins of Saint Louis encephalitis virus. J Virol (1971) 1.43
Structure and chemical-physical characteristics of lactate dehydrogenase-elevating virus and its RNA. J Virol (1975) 1.33
Dengue virions and antigens in brain and serum of infected mice. J Virol (1970) 1.30
Cytological localization of Dengue-2 antigens: an immunological study with ultrastructural correlation. Infect Immun (1973) 1.26
Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A (2011) 1.24
Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes. J Virol (2004) 1.24
Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. J Virol (2009) 1.10
Infection of bone marrow cells by dengue virus in vivo. Exp Hematol (2011) 1.02
Dengue virus infection of mice: morphology and morphogenesis of dengue type-2 virus in suckling mouse neurones. Infect Immun (1973) 0.98
Group B arbovirus structural and nonstructural antigens. I. Serological identification of Saint Louis encephalitis virus soluble antigens. Infect Immun (1973) 0.95
Effects of cell culture and laboratory conditions on type 2 dengue virus infectivity. J Clin Microbiol (1979) 0.95
The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology (2010) 0.94
Rapid preparation of hemagglutinins of togaviruses from infected cell culture fluids. Appl Microbiol (1972) 0.89
High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses. PLoS Negl Trop Dis (2013) 0.89
Replication of dengue virus type 2 in Aedes albopictus cell culture. J Virol (1973) 0.88
Role of microparticles in dengue virus infection and its impact on medical intervention strategies. Yale J Biol Med (2012) 0.87
Virion and soluble antigens of japanese encephalitis virus. Infect Immun (1975) 0.86
Differential requirements in endocytic trafficking for penetration of dengue virus. PLoS One (2012) 0.86
Group B arbovirus structural and nonstructural antigens. II. Purification of Saint Louis encephalitis virus intracellular antigens. Infect Immun (1973) 0.85
Reactions of purified hemagglutinating antigens of flaviviruses with 19S and 7S antibodies. Infect Immun (1975) 0.84
Immune response in rabbits to virion and nonvirion antigens of the Flavivirus kunjin. Infect Immun (1977) 0.83
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. Biomed Res Int (2013) 0.80
Ultrastructural studies on dengue virus infection of human lymphoblasts. Infect Immun (1978) 0.78
Effect of urea on the hemagglutinating and complement-fixing antigens of type 2 Dengue virus. Infect Immun (1972) 0.77
Mosquito cell-derived West Nile virus replicon particles mimic arbovirus inoculum and have reduced spread in mice. PLoS Negl Trop Dis (2017) 0.75
Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearance. Sci Rep (2015) 0.75
Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg (1958) 40.44
Production and characterization of arbovirus antibody in mouse ascitic fluid. Am J Trop Med Hyg (1967) 2.61
Dengue virus identification by the plaque reduction neutralization test. J Immunol (1967) 2.45
Studies on the nature of dengue viruses. II. Characterization of viral RNA and effects of inhibitors of RNA synthesis. Virology (1966) 1.74
Studies on the nature of dengue viruses. I. Correlation of particle density, infectivity, and RNA content of type 2 virus. Virology (1965) 1.58
Immunologic studies of Japanese encephalitis virus in Japan. I. Antibody responses following overt infection of man. J Immunol (1959) 1.20
Investigations on complement-fixing subunits of a group A arbo virus (Sindbis). Virology (1966) 1.08
Fractionation of Eastern equine encephalitis virus by density gradient centrifugation in CsCl. J Virol (1968) 1.00
Some physical properties of hemagglutinating and complement-fixing particles of Semliki Forest virus. Virology (1961) 0.94
Some fundamental characteristics of dengue and yellow fever viruses: inhomogeneity and characterization of partially purified viral particles. Kobe J Med Sci (1967) 0.92
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol (1989) 7.06
Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg (1989) 4.79
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg (1982) 4.04
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Telling the truth about terminal cancer. JAMA (1998) 3.07
Congenital rubella. Clinicopathologic, virologic, and immunologic studies. Am J Dis Child (1965) 2.82
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infect Immun (1976) 2.67
Production and characterization of arbovirus antibody in mouse ascitic fluid. Am J Trop Med Hyg (1967) 2.61
Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49
Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47
Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46
Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46
Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42
Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg (1982) 2.41
Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39
A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
Herpesvirus infections of the human central nervous system. N Engl J Med (1967) 2.09
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07
Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg (1985) 2.04
Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00
The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97
Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay. Am J Trop Med Hyg (1983) 1.96
Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis (1971) 1.95
Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol (1989) 1.92
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res (2000) 1.86
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80
Replication of dengue-2 virus in cultured human lymphoblastoid cells and subpopulations of human peripheral leukocytes. J Immunol (1976) 1.79
Acute respiratory disease and meningococcal infection in army recruits. JAMA (1967) 1.73
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71
Measuring standards of care for early breast cancer in an insured population. J Clin Oncol (1997) 1.71
Immunoprecipitation analysis of soluble complement-fixing antigens of dengue viruses. J Immunol (1970) 1.69
Change involving a viral membrane glycoprotein during morphogenesis of group B arboviruses. Virology (1972) 1.69
Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants. Infect Immun (1982) 1.69
Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67
Immunological and biophysical separation of dengue-2 antigens. J Virol (1971) 1.66
Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Virol (1984) 1.66
The proteins of Japanese encephalitis virus. Virology (1971) 1.63
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62
Pulmonary function in firefighters: acute changes in ventilatory capacity and their correlates. Br J Ind Med (1979) 1.61
Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol (1989) 1.59
Evidence for two mechanisms of dengue virus infection of adherent human monocytes: trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors. Infect Immun (1981) 1.58
The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR Am J Roentgenol (1994) 1.54
Safety, accuracy, and diagnostic yield of needle localization biopsy of the breast performed using local anesthesia. J Am Coll Surg (1994) 1.49
Modeling particle exposure in U.S. trucking terminals. Environ Sci Technol (2006) 1.49
Dose coefficients for the embryo and foetus following intakes of radionuclides by the mother. J Radiol Prot (2002) 1.47
The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol (1992) 1.45
Effect of passage history on dengue-2 virus replication in subpopulations of human leukocytes. Infect Immun (1979) 1.44
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43
Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab (2001) 1.42
Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia (2006) 1.42
The use of viscoelastic substances in the drainage of postoperative suprachoroidal hemorrhage. Ophthalmic Surg (1989) 1.40
Deletions of fetal and adult muscle cDNA in Duchenne and Becker muscular dystrophy patients. EMBO J (1987) 1.40
Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun (1998) 1.39
Fungal virus capsids, cytoplasmic compartments for the replication of double-stranded RNA, formed as icosahedral shells of asymmetric Gag dimers. J Mol Biol (1994) 1.39
Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States. Environ Health Perspect (1993) 1.39
Electron microscopic observations on Herpesvirus hominis (herpes simplex virus) encephalitis in man. Lab Invest (1966) 1.39
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol (1999) 1.39
Pulmonary effects of exposures in silicon carbide manufacturing. Br J Ind Med (1984) 1.39
Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing quadrant. Int J Radiat Oncol Biol Phys (1993) 1.38
Partial purification and characterization of a dengue virus soluble complement-fixing antigen. J Immunol (1970) 1.37
Corneal traction suture in trabeculectomy. Ophthalmic Surg (1991) 1.37
Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol (1971) 1.36
Estimation of the diesel exhaust exposures of railroad workers: I. Current exposures. Am J Ind Med (1988) 1.35
Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg (1995) 1.35
Human lung tryptase. Purification and characterization. J Biol Chem (1984) 1.33
Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis (1971) 1.33
Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol (1998) 1.32
Dengue virions and antigens in brain and serum of infected mice. J Virol (1970) 1.30
Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc (1984) 1.30
Human immunoglobulin specificity after group B arbovirus infections. Infect Immun (1972) 1.29
Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice. Proc Natl Acad Sci U S A (1993) 1.28
Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun (1981) 1.28
Herpes simplex virus infections of the nervous system. Problems in laboratory diagnosis. Arch Neurol (1968) 1.27
Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat (1996) 1.27
Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis (1983) 1.27